Imatinib mesylate is extremely active in Philadelphia-positive (Ph+) chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), but it’s effect on the outcome of a subsequent allogeneic stem cell transplantation (SCT) is still a matter of debate. We report our experience in ten cases of Ph+ leukaemias (4 ALL and 6 CML) who underwent SCT after Imatinib therapy and compared to 39 historical controls (30 CML and 9 ALL) transplanted without Imatinib pre-treatment. No difference was seem in terms of engraftment, time to recovery, incidence of acute and chronic graft-versus-host disease (GVHD) and infections.
Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias
TIRIBELLI, Mario;DAMIANI, Daniela;FANIN, Renato
2004-01-01
Abstract
Imatinib mesylate is extremely active in Philadelphia-positive (Ph+) chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), but it’s effect on the outcome of a subsequent allogeneic stem cell transplantation (SCT) is still a matter of debate. We report our experience in ten cases of Ph+ leukaemias (4 ALL and 6 CML) who underwent SCT after Imatinib therapy and compared to 39 historical controls (30 CML and 9 ALL) transplanted without Imatinib pre-treatment. No difference was seem in terms of engraftment, time to recovery, incidence of acute and chronic graft-versus-host disease (GVHD) and infections.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
16. bmt 2004.pdf
non disponibili
Tipologia:
Altro materiale allegato
Licenza:
Non pubblico
Dimensione
73.17 kB
Formato
Adobe PDF
|
73.17 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.